BioXcel Therapeutics Inc (NASDAQ:BTAI) Director Peter Mueller purchased 4,007 shares of the business’s stock in a transaction on Tuesday, December 4th. The stock was purchased at an average price of $5.13 per share, for a total transaction of $20,555.91. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Peter Mueller also recently made the following trade(s):
- On Friday, December 7th, Peter Mueller purchased 8,795 shares of BioXcel Therapeutics stock. The stock was purchased at an average price of $5.01 per share, for a total transaction of $44,062.95.
Shares of NASDAQ:BTAI opened at $4.73 on Friday. BioXcel Therapeutics Inc has a 52-week low of $4.65 and a 52-week high of $14.79.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.05). On average, research analysts anticipate that BioXcel Therapeutics Inc will post -1.2 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Creative Planning bought a new position in shares of BioXcel Therapeutics in the third quarter valued at approximately $102,000. Point72 Asset Management L.P. lifted its holdings in shares of BioXcel Therapeutics by 10.7% in the second quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after purchasing an additional 6,358 shares in the last quarter. BlackRock Inc. bought a new position in shares of BioXcel Therapeutics in the second quarter valued at approximately $137,000. Artemis Investment Management LLP lifted its holdings in shares of BioXcel Therapeutics by 1.3% in the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock valued at $9,700,000 after purchasing an additional 16,358 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of BioXcel Therapeutics in the first quarter valued at approximately $316,000. Institutional investors own 20.79% of the company’s stock.
BTAI has been the topic of several recent research reports. Canaccord Genuity reiterated a “buy” rating and issued a $21.00 price target on shares of BioXcel Therapeutics in a report on Friday, August 10th. Zacks Investment Research upgraded BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Tuesday, August 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $18.67.
ILLEGAL ACTIVITY NOTICE: “Peter Mueller Acquires 4,007 Shares of BioXcel Therapeutics Inc (BTAI) Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/08/peter-mueller-acquires-4007-shares-of-bioxcel-therapeutics-inc-btai-stock.html.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Story: Capital Gains
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.